2-(2,5-Dioxopyrrol-1-yl)-4-oxopentanal

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 2-(2,5-Dioxopyrrol-1-yl)-4-oxopentanal
• 英文别名: 2-(2,5-dioxopyrrol-1-yl)-4-oxopentanal
• 化学式: C₉H₉NO₄
• 分子量: 195.17
• InChiKey: CSMJAKSILVNRJE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  71.5
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Modulators of coagulation factors with enhanced stability
  申请人：Rusconi Christopher P.

  公开号：US20080125383A1

  公开（公告）日：2008-05-29

  The invention provides improved nucleic acid ligands with enhanced stability that inhibit coagulation and improved modulators of the nucleic acids to provide ideal modulators of coagulation. These improved nucleic acids and modulators are particularly useful for inhibiting coagulation in a host undergoing a therapeutic regime such as surgery or coronary artery bypass.
• NUCLEIC ACID MODULATORS OF GLYCOPROTEIN VI
  申请人：Layzer Juliana M.

  公开号：US20100311820A1

  公开（公告）日：2010-12-09

  The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.
• METHOD FOR MANUFACTURING PEGYLATED OLIGONUCLEOTIDES
  申请人：BROOKS DOUGLAS

  公开号：US20120277419A1

  公开（公告）日：2012-11-01

  A method for preparing a therapeutic pegylated oligonucleotide is described. The method involves synthesis, cleavage and purification steps designed to improve the efficiency whereby the therapeutic oligonucleotide may be prepared. Also described are methods for large scale preparation at the improved efficiency.
• US7531524B2
  申请人：——

  公开号：US7531524B2

  公开（公告）日：2009-05-12
• US8318923B2
  申请人：——

  公开号：US8318923B2

  公开（公告）日：2012-11-27